← All trials
NCT04079166
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 19, 2019
- Primary completion
- Jan 31, 2026
- Completion date
- Jan 31, 2026
- First posted
- Sep 6, 2019
- Last posted
- Oct 31, 2023
- Enrollment
- 87
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Scancell LtdLead sponsor
- University of NottinghamOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.